Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of May 2025, specifically detailing share repurchases executed on May 8, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific block of share buybacks executed as part of an existing program. No revenue, profit, or cash flow data is provided in this specific document.
- Transaction Date: May 8, 2025
- Shares Purchased: 680,805 ordinary shares
- Price Range: 1,356.50p (Low) to 1,382.00p (High)
- Volume-Weighted Average Price (VWAP): 1,366.85p
- Trading Venue: London Stock Exchange (XLON)
- Broker: Citigroup Global Markets Limited
- Treasury Shares Held: 208,278,000 (post-transaction)
- Shares in Issue (excluding Treasury): 4,106,968,502
- Total Voting Rights: 4,106,968,502
Material Changes and Program Progress
The purchase was effected pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, GSK has purchased an aggregate of 39,207,697 ordinary shares. The shares purchased in this transaction are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the non-discretionary agreement since February 24, 2025 (stated as 39,207,697).
- Confirm the current number of shares in issue excluding Treasury shares (stated as 4,106,968,502) for voting rights calculations.
- Review the "Risk Factors" section in the 2024 Form 20-F and Q1 2025 results for context on forward-looking statements.
- Check subsequent filings for updates on the remaining capacity of the buyback program.